Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson’s disease: A prospective analysis of Thai Apomorphine Registry
Objective: To evaluate a reduction of LED in PD patients who achieve satisfactory motor control with long-term continuous subcutaneous apomorphine infusion (CSAI) Background: Apomorphine is…Quality of Life Study of Patients Living with Parkinson’s Disesae in Sub-Saharan Africa
Objective: The objective is to assess the quality of life of patients with Parkinson's disease followed in Senegal. Background: Parkinson's disease is a neurodegenerative disease,…Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study
Objective: To evaluate the long-term efficacy of APO in PD patients treated at two specialist centres in Spain and Thailand, and to determine the reasons…Predictors of refractory impulse control disorder to dopamine agonists substitution therapy in Parkinson’s disease patients
Objective: This study was aimed to investigate a predictive factor of refractory impulse control disorder (ICD) in patients with Parkinson’s disease (PD) who participated in…Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease
Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…A study for expanding application sites of rotigotine transdermal patch
Objective: We examined to see whether to expand application sites of RTP other than the approved application sites. Background: Rotigotine transdermal patch (RTP) is a dopamine…The Frequency, Causes and Risk Factors of Discontinuation of Dopamine Agonists in Parkinson’s Disease Patients
Objective: To determine the incidence, causes and risk factors of dopamine agonists (pramipexole and ropinirole) discontinuation in Parkinson’s disease patients. Background: Ropinirole and pramipexole are…Behavioural aspect of transgenic Drosophila melanogaster as a model of Parkinson’s disease treated by Ropinirole alginate nanocomposite
Objective: To evaluate the behavioural changes in transgenic Drosophila melanogaster as a model of Parkinson’s disease treated by different doses of Ropinirole alginate nanocomposite (RANC).…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 15
- Next Page »